Autism Spectrum Disorder Trial, Recruiting (NCT06733584)

Autism Spectrum Disorder Trial, Recruiting NCT06733584 Sponsor: The University of Texas at Dallas Condition: Autism Spectrum Disorder

Printed from Voxsanity (voxsanity.com.au) — NCT06733584 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Autism Spectrum Disorder

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The child must come from a Hispanic family with a low household income (specifically, a family income below 320% of the federal poverty level, based on household size)
The child must be between 18 and 42 months old at the time the study begins
The child must have no known neurological or genetic conditions, based on what parents report
The child must score 4 or higher on a standardised autism assessment called the ADOS-2, as measured by a qualified bilingual assessor
The family's main language spoken at home must be English, Spanish, or both

Who may not be able to join:

Children from families who are not Hispanic, or whose household income is at or above 320% of the federal poverty level
Children who are younger than 18 months or older than 42 months when the study starts
Children whose parents report any known neurological or genetic conditions
Children who score below 4 on the ADOS-2 autism assessment
Families whose primary home language is neither English nor Spanish

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pamela Rollins, EdD, The University of Texas at Dallas

Phone: 972-883-3153

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06733584

Sponsor: The University of Texas at Dallas

Phase: Not Applicable

Status: Recruiting

Condition: Autism Spectrum Disorder

Trial contact: 972-883-3153

More information: https://clinicaltrials.gov/study/NCT06733584

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The child must come from a Hispanic family with a low household income (specifically, a family income below 320% of the federal poverty level, based on household size)
The child must be between 18 and 42 months old at the time the study begins
The child must have no known neurological or genetic conditions, based on what parents report
The child must score 4 or higher on a standardised autism assessment called the ADOS-2, as measured by a qualified bilingual assessor
The family's main language spoken at home must be English, Spanish, or both

Who may not be able to join:

Children from families who are not Hispanic, or whose household income is at or above 320% of the federal poverty level
Children who are younger than 18 months or older than 42 months when the study starts
Children whose parents report any known neurological or genetic conditions
Children who score below 4 on the ADOS-2 autism assessment
Families whose primary home language is neither English nor Spanish

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

The University of Texas at Dallas

Registry

ClinicalTrials.gov

Start date

22 September 2025

Est. completion

1 January 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Respeto; Change in Social Communication Skills; Change in Adaptive Functioning; Change in Social Attention; Change in Intentional Communication; Change in Expressive Language

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov